Oncomed Pharmaceuticals Inc (OMED) 25.99 $OMED
OncoMed Presents Data on Multiple Anti-Cancer Stem Cell Programs at American Association for Cancer Research Annual Meeting
GlobeNewswire - Tue Apr 08, 8:39AM CDT
OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today announced data from an oral presentation and eight poster presentations at the American Association of Cancer Research (AACR) Annual Meeting in San Diego, CA April 5-9, 2014. The research presented at AACR highlight OncoMed's drug discovery platforms along with preclinical and biomarker discoveries on its clinical-stage product candidates and several emerging product candidates. A brief summary of each presentation is provided below.
Nasdaq stocks posting largest percentage decreases
AP - Fri Apr 04, 5:20PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Healthcare Companies Report Transactions, Appeals, New Research Findings and Stock Movements - Analyst Notes on Johnson & Johnson, Teva, Celgene, Cara Therapeutics, and OncoMed Pharmaceuticals
PR Newswire - Thu Apr 03, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Johnson & Johnson (NYSE: JNJ), Teva Pharmaceutical Industries Limited (NYSE: TEVA), Celgene Corporation (NASDAQ: CELG), Cara Therapeutics Inc. (NASDAQ: CARA), and OncoMed Pharmaceuticals, Inc. (NASDAQ: OMED). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Celgene Extends Ties with Forma Therapeutics - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 02, 10:40AM CDT
Celgene expanded its partnership with the privately held Forma Therapeutics.
Pharma & Biotech Stock Outlook - March 2014 - Zacks Analyst Interviews
Arpita Dutt - Zacks Investment Research - Wed Mar 26, 1:17AM CDT
Pharma & Biotech Stock Outlook - March 2014 - Zacks Analyst Interviews
Pharma & Biotech Stock Outlook - March 2014 - Industry Outlook
Arpita Dutt - Zacks Investment Research - Wed Mar 26, 1:17AM CDT
Pharma & Biotech Stock Outlook - March 2014 - Industry Outlook
Candidate Selection for Clinical Trials, Financial Results, and Patient Enrollments for Phase I Study - Analyst Notes on Synta, Ziopharm, Aastrom, Agios, and OncoMed
PR Newswire - Tue Mar 25, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Synta Pharmaceuticals Corp. (NASDAQ: SNTA), ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP), Aastrom Biosciences, Inc. (NASDAQ: ASTM), Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), and OncoMed Pharmaceuticals, Inc. (NASDAQ: OMED). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Adams Street Partners Venture Funds Achieve Three IPOs in Consecutive Days
Business Wire - Mon Mar 24, 3:04PM CDT
Adams Street Partners, LLC ("ASP"
, a global private equity firm, announced today that three of its portfolio companies launched IPOs in successive days last week. The three companies represent investments made by Adams Street Partners' direct venture capital and growth equity team.
OncoMed's Q4 Loss Narrows - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 20, 1:50PM CDT
OncoMed reported a loss of 15 cents per share, narrower than the year-ago loss of $4.01 per share but missing the Zacks Consensus Estimate earnings of 4 cents per share.
OncoMed Pharmaceuticals Announces Full Year and Fourth Quarter 2013 Financial Results
GlobeNewswire - Tue Mar 18, 7:43AM CDT
Year-End Cash and Cash Equivalents Balance of $316.2 Million Reflecting IPO and Celgene Multi-Product Co-Development Collaboration
The 5 Most Hated Biotechs: Myriad, Sarepta, OncoMed, VIVUS, and MannKind
Brian Orelli, The Motley Fool - Motley Fool - Thu Mar 13, 5:30PM CDT
Not every company in biotech land is loved by investors. In fact, many biotechs top the list of companies with high short interest as a percentage of float. As of the end of February, Myriad Genetics was the second-most shorted company as a...
OncoMed to Present Data on Anti-Cancer Stem Cell Candidates at the American Association of Cancer Research Meeting
GlobeNewswire - Thu Mar 06, 8:24AM CST
OncoMed Pharmaceuticals Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today announced that it will provide an extensive update on its anti-cancer stem cell pipeline at the upcoming American Association of Cancer Research (AACR) meeting to be held April 5-9, 2014 in at the San Diego Convention Center in San Diego, CA.
What You Ought To Know About Celgene's Deal-Making Magic
Todd Campbell, The Motley Fool - Motley Fool - Wed Mar 05, 5:30PM CST
Celgene , the biotech giant best known for its $4 billion a year myeloma drug Revlimid, has been among the most active in making deals with young biotech companies. In January, Celgene made its latest deal, handing over $50 million to cozy up to...
5 States Where Pancreatic Cancer Prevalence Is the Highest
Sean Williams, The Motley Fool - Motley Fool - Sat Mar 01, 11:15AM CST
There is no making light of the fact that cancer is a terrible disease, claiming more lives in the U.S. each year save for heart disease. What's even scarier is that cancer prevalence is rising in the U.S., whereas a number of other leading causes of...
OncoMed Pharmaceuticals to Present at the Cowen and Company 34th Annual Health Care Conference
GlobeNewswire - Fri Feb 28, 7:30AM CST
OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today announced that Paul J. Hastings, OncoMed's Chairman and Chief Executive Officer, will speak at the Cowen and Company 34th Annual Health Care Conference being held at the Boston Marriott Copley Place in Boston, MA.
OncoMed Commences Study on OMP-54F28 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 21, 3:50PM CST
OncoMed Pharma announced that it has commenced the third phase Ib study on OMP-54F28 in patients with platinum-sensitive ovarian cancer
Bispecific Antibodies: Clinical Trial Tracker
M2 - Fri Feb 21, 4:31AM CST
Research and Markets (http://www.researchandmarkets.com/research/kmc65d/bispecific) has announced the addition of the "Bispecific Antibodies: Clinical Trial Tracker" report to their offering. Bispecific antibodies (bsAbs) are artificial antibodies created by joining together two monoclonal antibodies (or parts) that target different epitopes. The resulting antibody has binding affinities for two or three different epitopes concurrently. Various technology platforms have been used for bsAbs production over the years. These platforms are based on the concepts of chemical crosslinking, hybrid hybridomas, with the latest being recombinant techniques. Different binding sites can be exploited to produce bispecific systems with different mechanisms, such as the T cell engager system. As of now, only one bsAb, Removab, approved for malignant ascites is available in the market. The focus of the pipeline drugs is on oncology as well as on non-oncological indications such as rheumatoid arthritis and other inflammatory diseases. The primary objective of this report is to capture details on the various clinical and preclinical trials which are currently underway in the field of Antibody Drug Conjugates. A number of such trials which are taking place for a variety of indications across multiple geographies have been identified. The information has also been presented in the form a dashboard to provide a high level quick overview of the ongoing activity in this space. In addition to the clinical trial details, the report also provides the following: Detailed forecasts of the bispecific antibody market over the course of next ten years. Owing to the niche nature of this market, we have presented three scenarios to add robustness to our market forecast. The conservative, base and optimistic scenarios represent three different tracks of industry evolution. Industry SWOT analysis summarising the challenges as well as opportunities in the market for different stakeholders Key Topics Covered: I. Introduction and Pipeline Details Section 1: Market Overview Section 2: Dashboard: Pipeline Analysis Section 3: Molecules in Clinical Development: Trial Details Section 4: Molecules in Preclinical Development: Trial Details Section 5: Inclusion / Exclusion Criteria II Market Forecast, 2013 - 2023 Section 6: Market Forecast: Assumptions Section 7: Market Forecast: Details Section 8: Comparative Forecast Scenarios III. Industry Analysis Section 9: Industry SWOT Analysis List of Figures List of Tables Companies Mentioned - AbbVie - Baliopharm - Celgene - Dutalys - Eddingpharm - Fabion Pharmaceuticals - Ganymed Pharmaceuticals - Ho Research Consortium - ImClone System - Janssen Biotech - Krankenhaus Nordwest - MacroGenics - Nantes University Hospital - OncoMed Pharmaceuticals - Paktis Antibody Services GmbH - Radboud University - Sanofi - Technische Universit?t M?nchen - University Hospital Tuebingen - Xencor - Zymeworks and many more... For more information visit http://www.researchandmarkets.com/research/kmc65d/bispecific About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
OncoMed Pharmaceuticals Commences Third Phase 1b Clinical Trial for OMP-54F28 (Fzd8-Fc) With Carboplatin and Paclitaxel in Ovarian Cancer
GlobeNewswire - Thu Feb 20, 7:30AM CST
OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today announced the initiation of patient treatment for its third multi-center Phase 1b clinical trial of OMP-54F28 (Fzd8-Fc) with carboplatin and paclitaxel in patients with platinum-sensitive ovarian cancer. OMP-54F28 is a first-in-class decoy receptor targeting the Wnt pathway and is part of OncoMed's collaboration with Bayer Pharma AG (Bayer).
OncoMed Presents Data on Multiple Anti-Cancer Stem Cell Programs at American Association for Cancer Research Annual Meeting
GlobeNewswire - Tue Apr 08, 8:39AM CDT
OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today announced data from an oral presentation and eight poster presentations at the American Association of Cancer Research (AACR) Annual Meeting in San Diego, CA April 5-9, 2014. The research presented at AACR highlight OncoMed's drug discovery platforms along with preclinical and biomarker discoveries on its clinical-stage product candidates and several emerging product candidates. A brief summary of each presentation is provided below.
Nasdaq stocks posting largest percentage decreases
AP - Fri Apr 04, 5:20PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Healthcare Companies Report Transactions, Appeals, New Research Findings and Stock Movements - Analyst Notes on Johnson & Johnson, Teva, Celgene, Cara Therapeutics, and OncoMed Pharmaceuticals
PR Newswire - Thu Apr 03, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Johnson & Johnson (NYSE: JNJ), Teva Pharmaceutical Industries Limited (NYSE: TEVA), Celgene Corporation (NASDAQ: CELG), Cara Therapeutics Inc. (NASDAQ: CARA), and OncoMed Pharmaceuticals, Inc. (NASDAQ: OMED). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Celgene Extends Ties with Forma Therapeutics - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 02, 10:40AM CDT
Celgene expanded its partnership with the privately held Forma Therapeutics.
Pharma & Biotech Stock Outlook - March 2014 - Zacks Analyst Interviews
Arpita Dutt - Zacks Investment Research - Wed Mar 26, 1:17AM CDT
Pharma & Biotech Stock Outlook - March 2014 - Zacks Analyst Interviews
Pharma & Biotech Stock Outlook - March 2014 - Industry Outlook
Arpita Dutt - Zacks Investment Research - Wed Mar 26, 1:17AM CDT
Pharma & Biotech Stock Outlook - March 2014 - Industry Outlook
Candidate Selection for Clinical Trials, Financial Results, and Patient Enrollments for Phase I Study - Analyst Notes on Synta, Ziopharm, Aastrom, Agios, and OncoMed
PR Newswire - Tue Mar 25, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Synta Pharmaceuticals Corp. (NASDAQ: SNTA), ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP), Aastrom Biosciences, Inc. (NASDAQ: ASTM), Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), and OncoMed Pharmaceuticals, Inc. (NASDAQ: OMED). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Adams Street Partners Venture Funds Achieve Three IPOs in Consecutive Days
Business Wire - Mon Mar 24, 3:04PM CDT
Adams Street Partners, LLC ("ASP"
, a global private equity firm, announced today that three of its portfolio companies launched IPOs in successive days last week. The three companies represent investments made by Adams Street Partners' direct venture capital and growth equity team. OncoMed's Q4 Loss Narrows - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 20, 1:50PM CDT
OncoMed reported a loss of 15 cents per share, narrower than the year-ago loss of $4.01 per share but missing the Zacks Consensus Estimate earnings of 4 cents per share.
OncoMed Pharmaceuticals Announces Full Year and Fourth Quarter 2013 Financial Results
GlobeNewswire - Tue Mar 18, 7:43AM CDT
Year-End Cash and Cash Equivalents Balance of $316.2 Million Reflecting IPO and Celgene Multi-Product Co-Development Collaboration
The 5 Most Hated Biotechs: Myriad, Sarepta, OncoMed, VIVUS, and MannKind
Brian Orelli, The Motley Fool - Motley Fool - Thu Mar 13, 5:30PM CDT
Not every company in biotech land is loved by investors. In fact, many biotechs top the list of companies with high short interest as a percentage of float. As of the end of February, Myriad Genetics was the second-most shorted company as a...
OncoMed to Present Data on Anti-Cancer Stem Cell Candidates at the American Association of Cancer Research Meeting
GlobeNewswire - Thu Mar 06, 8:24AM CST
OncoMed Pharmaceuticals Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today announced that it will provide an extensive update on its anti-cancer stem cell pipeline at the upcoming American Association of Cancer Research (AACR) meeting to be held April 5-9, 2014 in at the San Diego Convention Center in San Diego, CA.
What You Ought To Know About Celgene's Deal-Making Magic
Todd Campbell, The Motley Fool - Motley Fool - Wed Mar 05, 5:30PM CST
Celgene , the biotech giant best known for its $4 billion a year myeloma drug Revlimid, has been among the most active in making deals with young biotech companies. In January, Celgene made its latest deal, handing over $50 million to cozy up to...
5 States Where Pancreatic Cancer Prevalence Is the Highest
Sean Williams, The Motley Fool - Motley Fool - Sat Mar 01, 11:15AM CST
There is no making light of the fact that cancer is a terrible disease, claiming more lives in the U.S. each year save for heart disease. What's even scarier is that cancer prevalence is rising in the U.S., whereas a number of other leading causes of...
OncoMed Pharmaceuticals to Present at the Cowen and Company 34th Annual Health Care Conference
GlobeNewswire - Fri Feb 28, 7:30AM CST
OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today announced that Paul J. Hastings, OncoMed's Chairman and Chief Executive Officer, will speak at the Cowen and Company 34th Annual Health Care Conference being held at the Boston Marriott Copley Place in Boston, MA.
OncoMed Commences Study on OMP-54F28 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 21, 3:50PM CST
OncoMed Pharma announced that it has commenced the third phase Ib study on OMP-54F28 in patients with platinum-sensitive ovarian cancer
Bispecific Antibodies: Clinical Trial Tracker
M2 - Fri Feb 21, 4:31AM CST
Research and Markets (http://www.researchandmarkets.com/research/kmc65d/bispecific) has announced the addition of the "Bispecific Antibodies: Clinical Trial Tracker" report to their offering. Bispecific antibodies (bsAbs) are artificial antibodies created by joining together two monoclonal antibodies (or parts) that target different epitopes. The resulting antibody has binding affinities for two or three different epitopes concurrently. Various technology platforms have been used for bsAbs production over the years. These platforms are based on the concepts of chemical crosslinking, hybrid hybridomas, with the latest being recombinant techniques. Different binding sites can be exploited to produce bispecific systems with different mechanisms, such as the T cell engager system. As of now, only one bsAb, Removab, approved for malignant ascites is available in the market. The focus of the pipeline drugs is on oncology as well as on non-oncological indications such as rheumatoid arthritis and other inflammatory diseases. The primary objective of this report is to capture details on the various clinical and preclinical trials which are currently underway in the field of Antibody Drug Conjugates. A number of such trials which are taking place for a variety of indications across multiple geographies have been identified. The information has also been presented in the form a dashboard to provide a high level quick overview of the ongoing activity in this space. In addition to the clinical trial details, the report also provides the following: Detailed forecasts of the bispecific antibody market over the course of next ten years. Owing to the niche nature of this market, we have presented three scenarios to add robustness to our market forecast. The conservative, base and optimistic scenarios represent three different tracks of industry evolution. Industry SWOT analysis summarising the challenges as well as opportunities in the market for different stakeholders Key Topics Covered: I. Introduction and Pipeline Details Section 1: Market Overview Section 2: Dashboard: Pipeline Analysis Section 3: Molecules in Clinical Development: Trial Details Section 4: Molecules in Preclinical Development: Trial Details Section 5: Inclusion / Exclusion Criteria II Market Forecast, 2013 - 2023 Section 6: Market Forecast: Assumptions Section 7: Market Forecast: Details Section 8: Comparative Forecast Scenarios III. Industry Analysis Section 9: Industry SWOT Analysis List of Figures List of Tables Companies Mentioned - AbbVie - Baliopharm - Celgene - Dutalys - Eddingpharm - Fabion Pharmaceuticals - Ganymed Pharmaceuticals - Ho Research Consortium - ImClone System - Janssen Biotech - Krankenhaus Nordwest - MacroGenics - Nantes University Hospital - OncoMed Pharmaceuticals - Paktis Antibody Services GmbH - Radboud University - Sanofi - Technische Universit?t M?nchen - University Hospital Tuebingen - Xencor - Zymeworks and many more... For more information visit http://www.researchandmarkets.com/research/kmc65d/bispecific About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
OncoMed Pharmaceuticals Commences Third Phase 1b Clinical Trial for OMP-54F28 (Fzd8-Fc) With Carboplatin and Paclitaxel in Ovarian Cancer
GlobeNewswire - Thu Feb 20, 7:30AM CST
OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today announced the initiation of patient treatment for its third multi-center Phase 1b clinical trial of OMP-54F28 (Fzd8-Fc) with carboplatin and paclitaxel in patients with platinum-sensitive ovarian cancer. OMP-54F28 is a first-in-class decoy receptor targeting the Wnt pathway and is part of OncoMed's collaboration with Bayer Pharma AG (Bayer).
